106928-50-1

Usage

Uses

Used in Scientific Research and Development:
METHYL-2-BOC-AMINO-4-PENTENOIC ACID is used as a research chemical for [application reason] in the field of organic chemistry. The protective t-butyloxycarbonyl group allows for controlled reactions and synthesis of more complex molecules, making it a valuable tool in the development of new compounds and materials.
Used in Pharmaceutical Industry:
METHYL-2-BOC-AMINO-4-PENTENOIC ACID is used as an intermediate in the synthesis of pharmaceutical compounds for [application reason]. Its protective group can be selectively removed to reveal reactive functional groups, facilitating the creation of drug candidates with desired properties.
Used in Material Science:
METHYL-2-BOC-AMINO-4-PENTENOIC ACID is used as a building block in the development of new materials for [application reason]. Its unique structure and reactivity can contribute to the creation of advanced materials with specific properties, such as improved strength, flexibility, or chemical resistance.

Upstream product

• 186581-53-3 diazomethane 
• 119479-32-2 2-((tert-butyloxycarbonyl)amino)-4-pentenoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 106-95-6 allyl bromide 
• 173306-81-5 acetyloxy[[(1,1-dimethylethoxy)carbonyl]amino]acetic acid methyl ester 
• 143979-15-1 2-tert-Butoxycarbonylamino-pent-4-enoic acid; compound with dicyclohexyl-amine 
• 74-88-4 methyl iodide 
• 50299-15-5 allylglycine methyl ester 
• 67-56-1 methanol 
• 1069-48-3 rac-allylglycine 
• 4248-19-5 tert-butyl carbazate 
• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 150749-03-4 methyl 2-(tert-butoxycarbonylamino)-2-hydroxyacetate 

Downstream Products

• 103-30-0 (E)-1,2-diphenyl-ethene 
• 885679-19-6 1-(5-chloro-2-methoxy-benzenesulfonyl)-5-fluoro-1,2,3,6-tetrahydro-pyridine-2-carboxylic acid methyl ester 
• 885679-23-2 5-fluoro-2-(2-methoxy-benzylcarbamoyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 885679-24-3 2-(4-chloro-3-trifluoromethyl-benzylcarbamoyl)-5-fluoro-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 824394-11-8 (5RS,2'RS)-5-(2-amino-2-carboxyethyl)-4,5-dihydroisoxazole-3-carboxylic acid 
• 824394-11-8 5-(2-amino-2-carboxyethyl)-4,5-dihydroisoxazole-3-carboxylic acid 
• 164298-41-3 1-tert-butyl 2-methyl (+/-)-3,6-dihydro-1,2(2H)-pyridinedicarboxylate 
• 123457-13-6 p-nitrobenzyl (2S*,5R*,7S*)-7-<<(1,1-dimethylethoxy)carbonyl>amino>-8-oxo-4-thia-1-azabicyclo<3.3.0>octane-2-carboxylate 
• 123468-22-4 (6S,7aR)-6-tert-Butoxycarbonylamino-5-oxo-5,6,7,7a-tetrahydro-pyrrolo[2,1-b]thiazole-3-carboxylic acid 4-nitro-benzyl ester 
• 123457-14-7 (3R,6R,7aS)-2-Benzoyloxy-6-tert-butoxycarbonylamino-5-oxo-hexahydro-pyrrolo[2,1-b]thiazole-3-carboxylic acid 4-nitro-benzyl ester 
• 796072-30-5 5-(4-bromophenyl)-2-tert-butoxycarbonylamino-4-pentenoic acid methyl ester 
• 894401-46-8 2-tert-butoxycarbonylamino-5-[4-(methyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid methyl ester 

Relevant academic research and scientific papers

Amino [13]-macrodilactones: Synthesis, derivatization, and structural motifs

Macrocycles draw their usefulness from an ability to balance size, shape, and functionality according to general principles. These structural parameters manifest as the conformations of macrocycles and ultimately their functions. Reported here are results of an investigation on [13]-macrodilactones that take up unique folded conformations based on the interplay of multi-atom planar units and sterics. The defining feature of this group of [13]-macrodilactones is the pendant amine group attached to the ring. Amidation of the ring generated analogs that were designed to imitate features of the macrocyclic natural product Teixobactin. We also show that intramolecular interactions, and the A-value of an acylated amine can explain the conformational preferences in macrocycles.

Zinc mediated addition of active halides to a glycine cation equivalent: Synthesis of N-Boc-L-propargylglycine

The reaction of allylic, benzylic and propargylic halides with zine in the presence of the glycine cation equivalent, methyl N-Boc-2-acetoxyglycine, affords Boc protected amino acid derivatives in high yield. Resolution of methyl N-Boc- propargylglycine w

New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity

A series of twelve fluorinated and non-fluorinated potential histone deacetylase inhibitors 25 was synthesized and their inhibitory activity was tested against rat liver histone deacetylase. The new inhibitors involve an enzyme binding element consisting of asparagine, glutamine or different short chain fluorinated or unfluorinated amino acids, a suberoyl spacer and a hydroxamic acid functionality, which is responsible for the inhibitory activity. The 4-fluoro-2-aminobutyric acid esters 1a,b, their 2-methyl derivatives 2a,b and the 2-amino-4-fluoropent-4-enoic acid esters 3a,b were synthesized by alkylation of glycine or alanine ester imides with bromofluoroethane or 2-fluoroallylbromide, respectively. Methyl 2-amino-5-fluorohex-5-enoate (4a) was prepared using 3-fluorobut-3-enyl tosylate or the iodide as alkylating reagents. An alternative pathway starting from Boc protected 3-iodo-L-alanine was more efficient. The latter method was also applied to synthesize the parent unfluorinated compound 4c using allylbromide as the alkylating reagent. The fluorinated compounds, tested as histone deacetylase inhibitors were slightly less active than comparable (S)-valine, (S)-phenylalanine or (S)-allylglycine derivatives that do not contain a fluorine atom. Interestingly, it was shown for the first time that the fluoro vinyl group which was proposed to be an aprotic amide mimic due to its electronic properties may serve as a bioisosteric replacement of a primary amide function. For the fluorinated analogs 25f (IC50 0.88 μM) and 25i (IC50 1.02 μM) a similar or an even enhanced inhibitory activity was observed compared to the unfluorinated parents 25g (IC50 0.67 μM) and 25j (IC50 1.79 μM) or the (S)-asparagine or (S)-glutamine derivatives 25l (IC50 2.10 μM) and 25m (IC50 3.90 μM).

THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS

A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS

A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.

3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES

A compound of Formula (I) in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Ring-opening Cross-metathesis (ROCM) as a novel tool for the ligation of peptides

The development of ring-opening cross-metathesis (ROCM) as a novel tool for the site-specific ligation of peptide units is reported. The resulting structural units at the site of ligation resulting from ROCM resemble proline as well as other known ss-turn

SUBSTITUTED AMINO CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

GLYCINE DERIVATIVE AND USE THEREOF

A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can retain an excellent therapeutic or preventive effect over a longer period.

RCM-mediated synthesis of trifluoromethyl-containing nitrogen heterocycles

(Chemical Equation Presented) A ring-closing metathesis mediated pathway to trifluoromethyl-containing piperidines is detailed. This involves the development of a synthetic route to a new (trifluoromethyl)allylating reagent via a Diels-Alder/retro-Diels-Alder strategy, its application in the synthesis of a series of trifluormethyl-substituted diolefin recursors for ring-closing metathesis, and eventually the successful cyclization of these precursor molecules into the corresponding functionalized piperidines.